TY - JOUR T1 - Prevalence of vitamin D is not associated with the COVID-19 epidemic in Europe. A judicial update of the existing evidence JF - medRxiv DO - 10.1101/2021.03.04.21252885 SP - 2021.03.04.21252885 AU - Dimitra Rafailia Bakaloudi AU - Michail Chourdakis Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/07/2021.03.04.21252885.abstract N2 - Background COVID-19 has emerged as a global pandemic, affecting nearly 104 million people worldwide as of February 4th 2021. In previous published studies, the association between the mean Vit D status of each country and COVID-19 infection rate, and mortality among the adult population in European countries was examined. The aim of this study was to re-examine the relationship between the Vit D status of each country and COVID-19 infection, recovery, and mortality using updated data and a different methodological approach.Methods Information only form the last decade on Vit D concentration/deficiency for each country was retrieved through literature search on PubMed® database. As of February, 4th 2021, COVID-19 infections and mortalities per one million population as well as total recoveries were extracted from the Worldometer website. The association between vitamin D deficiency and COVID-19 infection, recovery, and mortality were explored using correlation coefficients and scatterplots.Findings The prevalence of vitamin D deficiency among European countries ranged from 6.0 (Finland) to 75.5% (Turkey), with several countries facing more than 50% of vitamin D deficiency among their population. Non-significant correlations were observed between the number of COVID-19 infections (r=0.190; p=0.374), recoveries (rs=0.317, p=0.131), and mortalities (r=0.129; p=0.549) per one million population, with the prevalence of vitamin D deficiency.Interpretation Prevalence of vitamin D deficiency was not significantly associated with either number of infections, recoveries or mortality rate of COVID-19 among European countries. Thus, it is an important parameter to be considered when implementing preventive measures to face COVID-19.Funding NoneCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable1MOne million25(OH)D25-hydroxyvitamin D3ACE2Angiotensin-Converting Enzyme 2Ang (1-7)Angiotensin (1-7)ARSAcute Respiratory SyndromeCOVID-19Coronavirus disease 2019ECTSEuropean Calcified Tissue SocietyICUIntensive Care UnitISOInternational Organization for StandardizationMasRMas ReceptorRASRenin - Angiotensin SystemRCTRandomized controlled trialRICURespiratory Intermediate Care UnitSARS-CoV-2Severe Acute Respiratory Syndrome CoronavirusUVUltravioletUVBUltraviolet BVit DVitamin D ER -